In one of his last public statements as president of Applied Biosystems, Mike Hunkapiller wrapped up a presentation on ABI’s finances in July by identifying two important trends in life sciences research.

“The first is the trend to systems biology, or integrated science, and the second is the trend towards targeted medicine,” Hunkapiller said. “At Applied Biosystems, we need to ensure that we continue to introduce products that support these research trends.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.